Liquidia Corporation
NASDAQ:LQDABiotechnology
+$0.23 today
- Market cap
- $5.08B
- Beta
- 0.59
- P/E (TTM)
- 271.8
- EPS (TTM)
- $0.25
Volume 1.22M
Average 1.50M
LQDA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Liquidia CorporationNASDAQ: LQDA
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 989.3% from a year ago
Net receivables stood at $108.58M at the end of Q2 FY2026, up 989.3% from a year earlier and up 46.4% from the prior quarter. Over 3 fiscal years it compounded at +120.9% a year.
Context
- Net receivables amounted to 20.8% of total assets at the end of Q2 FY2026, up 16.9 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +989.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 54.09M USD
- Year-over-year change
- +1889.4%
- 4-year CAGR
- +106.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.09M | +1889.4% |
| FY2024 | 2024-12-31 | 2.72M | -33.0% |
| FY2023 | 2023-12-31 | 4.06M | -19.1% |
| FY2022 | 2022-12-31 | 5.02M | +67.8% |
| FY2021 | 2021-12-31 | 2.99M | — |
Net Receivables vs competitors
How LQDA compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +989.3% is the highest of 3, against a peer median of +136.5%.
- Net receivables amounts to 20.8% of total assets for LQDA, versus a peer median of 4.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $310.3M USD | -18.2% | +16.7% | 4.3% | |
| Jun 2026 | $215.33M USD | +291.3% | +68.0% | 10.2% | |
| Jun 2026 | $108.58M USD | +989.3% | +120.9% | 20.8% | |
VCREVicore Pharma Holding AB | Jun 2026 | SEK 0 SEK | — | — | 0.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LQDA) | — | +136.5% | +42.3% | 4.3% | |
Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 57.49M | 93.28M | 83.68M | 176.48M | 190.68M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.99M | 5.02M | 4.06M | 2.72M | 54.09M |
| Inventory | 0 | 0 | 0 | 241K | 0 |
| Other Current Assets | (381) | 1.51M | 2.16M | 5.67M | (54.09M) |
| Total Current Assets | 61.28M | 99.81M | 89.9M | 185.11M | 190.68M |
| Property, Plant & Equipment (Net) | 7.43M | 6.25M | 6.18M | 12.49M | 0 |
| Goodwill | 3.9M | 3.9M | 3.9M | 3.9M | 3.9M |
| Intangible Assets | 4.39M | 3.73M | 3.43M | 3.16M | 2.95M |
| Long-term Investments | 0 | 0 | 0 | 0 | 3.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 16.73M | 15.51M | 14.92M | 25.66M | 126.9M |
| Total Non-current Assets | 32.45M | 29.39M | 28.43M | 45.21M | 137.25M |
| Total Assets | 93.73M | 129.2M | 118.33M | 230.31M | 327.93M |
| Account Payables | 1.07M | 2.2M | 1.4M | 4.69M | 3.68M |
| Short-term Debt | 0 | 0 | 2.62M | 18.02M | 58.41M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.16M | 2.86M | 8.54M | 18.66M | 20.32M |
| Total Current Liabilities | 7.33M | 8.8M | 18.55M | 41.78M | 135.77M |
| Long-term Debt | 10.41M | 19.88M | 43.42M | 97.37M | 132.94M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 3.64M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.14M | 6.59M | 6.71M | 7.3M | 4.75M |
| Total Non-current Liabilities | 21.14M | 29.98M | 52.49M | 111.26M | 147.42M |
| Total Liabilities | 28.46M | 38.78M | 71.04M | 153.04M | 283.19M |
| Common Stock | 52K | 64K | 69K | 85K | 87K |
| Retained Earnings | (309.58M) | (350.6M) | (429.1M) | (559.49M) | (626.31M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 65.27M | 90.42M | 47.29M | 77.28M | 44.75M |
| Total Debt | 16.08M | 24.46M | 49.54M | 122.39M | 197.93M |
| Net Debt | (41.41M) | (68.82M) | (34.14M) | (54.09M) | 7.25M |
Liquidia Corporation
NASDAQ:LQDA
Intrinsic Alpha fair value
Locked
Current Price
$56.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.